MedDataX Logo

Safety and Efficacy of BI 10773 as add-on to Insulin Regimen in Patients With Type 2 Diabetes Mellitus

NCT ID: NCT01306214

Last Updated: 2014-06-17

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

566 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-02-28

Study Completion Date

2013-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This trial will evaluate use of BI 10773 as add-on to insulin regimen alone or with metformin in patients with typr 2 diabetes. Both lowering glucose and HbA1c and reducing the use of insulin in this population would provide significant new information for the BI 10773 use and would offer a potential new therapeutic option in this population.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

4 Week Treatment With Three Oral Doses of BI 10773 in Patients With Type 2 Diabetes

NCT00558571

Diabetes Mellitus, Type 2
COMPLETED PHASE1

Efficacy and Safety of Empagliflozin (BI 10773) in Type 2 Diabetes Patients on a Background of Pioglitazone Alone or With Metformin

NCT01210001

Diabetes Mellitus, Type 2
COMPLETED PHASE3

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 14332 CL as Tablet in Female and Male Patients With Type 2 Diabetes

NCT02212925

Diabetes Mellitus, Type 2
TERMINATED PHASE1

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Doses of BI 10773 Tablets

NCT01924767

Diabetes Mellitus, Type 2
COMPLETED PHASE1

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 1356 BS as Tablet in Patients With Type 2 Diabetes

NCT02183415

Diabetes Mellitus, Type 2
COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diabetes Mellitus, Type 2 Obesity

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

BI 10773 low dose

BI 10773 low dose once daily

Group Type EXPERIMENTAL

Placebo

Intervention Type DRUG

Placebo matching BI 10773 high dose

BI 10773

Intervention Type DRUG

BI 10773 low dose once daily

BI 10773 high dose

BI 10733 high dose once daily

Group Type EXPERIMENTAL

Placebo

Intervention Type DRUG

Placebo matching BI 10773 low dose

BI 10773

Intervention Type DRUG

BI 10773 high dose once daily

Placebo

Placebo tablets matching BI 10773

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Placebo matching BI 10773 low dose

Placebo

Intervention Type DRUG

Placebo matching BI 10773 high dose

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Placebo

Placebo matching BI 10773 low dose

Intervention Type DRUG

Placebo

Placebo matching BI 10773 low dose

Intervention Type DRUG

Placebo

Placebo matching BI 10773 high dose

Intervention Type DRUG

Placebo

Placebo matching BI 10773 high dose

Intervention Type DRUG

BI 10773

BI 10773 low dose once daily

Intervention Type DRUG

BI 10773

BI 10773 high dose once daily

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Diagnosis of T2DM prior to informed consent
2. Male and female patients on diet and exercise regimen who are pre-treated with multiple daily injections (MDI) of insulin alone or in combination with immediate or extended release metformin
3. Stable metformin therapy: daily dose \>=1500 mg/day or maximum tolerated dose
4. HbA1c \>=7.5% and \<=10% at screening

Exclusion Criteria

1. Uncontrolled hyperglycemia with a glucose level \>240 mg/dl (\>13.3 mmol/L) after an overnight fast during placebo run-in
2. Any contraindications to metformin according to the local label
3. Acute coronary syndrome, stroke or TIA within 3 months prior to informed consent
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Eli Lilly and Company

INDUSTRY

Sponsor Role collaborator

Boehringer Ingelheim

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Boehringer Ingelheim

Role: STUDY_CHAIR

Boehringer Ingelheim

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

1245.49.10005 Boehringer Ingelheim Investigational Site

Birmingham, Alabama, United States

Site Status

1245.49.10011 Boehringer Ingelheim Investigational Site

Chandler, Arizona, United States

Site Status

1245.49.10004 Boehringer Ingelheim Investigational Site

Tucson, Arizona, United States

Site Status

1245.49.10002 Boehringer Ingelheim Investigational Site

Corona, California, United States

Site Status

1245.49.10013 Boehringer Ingelheim Investigational Site

El Cajon, California, United States

Site Status

1245.49.10030 Boehringer Ingelheim Investigational Site

Lomita, California, United States

Site Status

1245.49.10014 Boehringer Ingelheim Investigational Site

Spring Valley, California, United States

Site Status

1245.49.10019 Boehringer Ingelheim Investigational Site

Westlake Village, California, United States

Site Status

1245.49.10024 Boehringer Ingelheim Investigational Site

Denver, Colorado, United States

Site Status

1245.49.10018 Boehringer Ingelheim Investigational Site

Hialeah, Florida, United States

Site Status

1245.49.10016 Boehringer Ingelheim Investigational Site

Miami, Florida, United States

Site Status

1245.49.10021 Boehringer Ingelheim Investigational Site

Blue Ridge, Georgia, United States

Site Status

1245.49.10009 Boehringer Ingelheim Investigational Site

Chicago, Illinois, United States

Site Status

1245.49.10015 Boehringer Ingelheim Investigational Site

Evansville, Indiana, United States

Site Status

1245.49.10023 Boehringer Ingelheim Investigational Site

Greenville, North Carolina, United States

Site Status

1245.49.10007 Boehringer Ingelheim Investigational Site

Fargo, North Dakota, United States

Site Status

1245.49.10006 Boehringer Ingelheim Investigational Site

Columbus, Ohio, United States

Site Status

1245.49.10025 Boehringer Ingelheim Investigational Site

Greer, South Carolina, United States

Site Status

1245.49.10022 Boehringer Ingelheim Investigational Site

Memphis, Tennessee, United States

Site Status

1245.49.10003 Boehringer Ingelheim Investigational Site

Austin, Texas, United States

Site Status

1245.49.10001 Boehringer Ingelheim Investigational Site

Dallas, Texas, United States

Site Status

1245.49.10031 Boehringer Ingelheim Investigational Site

Houston, Texas, United States

Site Status

1245.49.10033 Boehringer Ingelheim Investigational Site

Bountiful, Utah, United States

Site Status

1245.49.10032 Boehringer Ingelheim Investigational Site

Salt Lake City, Utah, United States

Site Status

1245.49.10026 Boehringer Ingelheim Investigational Site

Norfolk, Virginia, United States

Site Status

1245.49.10020 Boehringer Ingelheim Investigational Site

Renton, Washington, United States

Site Status

1245.49.32010 Boehringer Ingelheim Investigational Site

Bonheiden, , Belgium

Site Status

1245.49.32002 Boehringer Ingelheim Investigational Site

Edegem, , Belgium

Site Status

1245.49.32007 Boehringer Ingelheim Investigational Site

Huy, , Belgium

Site Status

1245.49.32014 Boehringer Ingelheim Investigational Site

Jette, , Belgium

Site Status

1245.49.32013 Boehringer Ingelheim Investigational Site

La Louvière, , Belgium

Site Status

1245.49.32012 Boehringer Ingelheim Investigational Site

Leuven, , Belgium

Site Status

1245.49.59003 Boehringer Ingelheim Investigational Site

Pleven, , Bulgaria

Site Status

1245.49.59004 Boehringer Ingelheim Investigational Site

Sofia, , Bulgaria

Site Status

1245.49.59001 Boehringer Ingelheim Investigational Site

Stara Zagora, , Bulgaria

Site Status

1245.49.57003 Boehringer Ingelheim Investigational Site

Barranquilla, , Colombia

Site Status

1245.49.57004 Boehringer Ingelheim Investigational Site

Bogotá, , Colombia

Site Status

1245.49.57005 Boehringer Ingelheim Investigational Site

Bogotá, , Colombia

Site Status

1245.49.57006 Boehringer Ingelheim Investigational Site

Bogotá, , Colombia

Site Status

1245.49.57002 Boehringer Ingelheim Investigational Site

Medellín, , Colombia

Site Status

1245.49.42003 Boehringer Ingelheim Investigational Site

Brno, , Czechia

Site Status

1245.49.42010 Boehringer Ingelheim Investigational Site

Brno, , Czechia

Site Status

1245.49.42013 Boehringer Ingelheim Investigational Site

Břeclav, , Czechia

Site Status

1245.49.42011 Boehringer Ingelheim Investigational Site

Chrudim, , Czechia

Site Status

1245.49.42009 Boehringer Ingelheim Investigational Site

Hodonín, , Czechia

Site Status

1245.49.42012 Boehringer Ingelheim Investigational Site

Svitavy56802, , Czechia

Site Status

1245.49.72001 Boehringer Ingelheim Investigational Site

Kuopio, , Finland

Site Status

1245.49.72002 Boehringer Ingelheim Investigational Site

Oulu, , Finland

Site Status

1245.49.72003 Boehringer Ingelheim Investigational Site

Turku, , Finland

Site Status

1245.49.33001 Boehringer Ingelheim Investigational Site

Grenoble, , France

Site Status

1245.49.33011 Boehringer Ingelheim Investigational Site

Le Creusot, , France

Site Status

1245.49.33012 Boehringer Ingelheim Investigational Site

Marseille, , France

Site Status

1245.49.33003 Boehringer Ingelheim Investigational Site

Nantes, , France

Site Status

1245.49.33010 Boehringer Ingelheim Investigational Site

Narbonne, , France

Site Status

1245.49.33004 Boehringer Ingelheim Investigational Site

Pierre-Bénite, , France

Site Status

1245.49.33007 Boehringer Ingelheim Investigational Site

Point-à-Pitre Cedex, , France

Site Status

1245.49.33008 Boehringer Ingelheim Investigational Site

Saint-Priest-en-Jarez, , France

Site Status

1245.49.33009 Boehringer Ingelheim Investigational Site

Vénissieux, , France

Site Status

1245.49.49104 Boehringer Ingelheim Investigational Site

Bosenheim, , Germany

Site Status

1245.49.49013 Boehringer Ingelheim Investigational Site

Dresden, , Germany

Site Status

1245.49.49101 Boehringer Ingelheim Investigational Site

Mainz, , Germany

Site Status

1245.49.49002 Boehringer Ingelheim Investigational Site

Neuwied, , Germany

Site Status

1245.49.49005 Boehringer Ingelheim Investigational Site

Saarbrücken, , Germany

Site Status

1245.49.49102 Boehringer Ingelheim Investigational Site

Wangen, , Germany

Site Status

1245.49.50201 Boehringer Ingelheim Investigational Site

Guatemala City, , Guatemala

Site Status

1245.49.50202 Boehringer Ingelheim Investigational Site

Guatemala City, , Guatemala

Site Status

1245.49.50203 Boehringer Ingelheim Investigational Site

Guatemala City, , Guatemala

Site Status

1245.49.50204 Boehringer Ingelheim Investigational Site

Guatemala City, , Guatemala

Site Status

1245.49.50205 Boehringer Ingelheim Investigational Site

Quetzaltenango, , Guatemala

Site Status

1245.49.52011 Boehringer Ingelheim Investigational Site

Aguascalientes, , Mexico

Site Status

1245.49.52012 Boehringer Ingelheim Investigational Site

Cuautla, , Mexico

Site Status

1245.49.52003 Boehringer Ingelheim Investigational Site

Durango, , Mexico

Site Status

1245.49.52005 Boehringer Ingelheim Investigational Site

Durango, , Mexico

Site Status

1245.49.52004 Boehringer Ingelheim Investigational Site

Guadalajara, , Mexico

Site Status

1245.49.52006 Boehringer Ingelheim Investigational Site

Guadalajara, , Mexico

Site Status

1245.49.52008 Boehringer Ingelheim Investigational Site

Guadalajara, , Mexico

Site Status

1245.49.52001 Boehringer Ingelheim Investigational Site

México, D.F., , Mexico

Site Status

1245.49.52002 Boehringer Ingelheim Investigational Site

Monterrey, , Mexico

Site Status

1245.49.52009 Boehringer Ingelheim Investigational Site

Monterrey, , Mexico

Site Status

1245.49.52010 Boehringer Ingelheim Investigational Site

Monterrey, , Mexico

Site Status

1245.49.51002 Boehringer Ingelheim Investigational Site

Arequipa, , Peru

Site Status

1245.49.51006 Boehringer Ingelheim Investigational Site

Arequipa, , Peru

Site Status

1245.49.51010 Boehringer Ingelheim Investigational Site

Jesus Maria, , Peru

Site Status

1245.49.51001 Boehringer Ingelheim Investigational Site

Lima, , Peru

Site Status

1245.49.51008 Boehringer Ingelheim Investigational Site

Lima, , Peru

Site Status

1245.49.51009 Boehringer Ingelheim Investigational Site

Lima, , Peru

Site Status

1245.49.70008 Boehringer Ingelheim Investigational Site

Moscow, , Russia

Site Status

1245.49.70009 Boehringer Ingelheim Investigational Site

Moscow, , Russia

Site Status

1245.49.70006 Boehringer Ingelheim Investigational Site

Saint Petersburg, , Russia

Site Status

1245.49.70010 Boehringer Ingelheim Investigational Site

Saint Petersburg, , Russia

Site Status

1245.49.34039 Boehringer Ingelheim Investigational Site

Ávila, , Spain

Site Status

1245.49.34038 Boehringer Ingelheim Investigational Site

Madrid, , Spain

Site Status

1245.49.34044 Boehringer Ingelheim Investigational Site

Madrid, , Spain

Site Status

1245.49.34043 Boehringer Ingelheim Investigational Site

MBoadilla Del Monte (Madrid), , Spain

Site Status

1245.49.34047 Boehringer Ingelheim Investigational Site

Palma de Mallorca, , Spain

Site Status

1245.49.34045 Boehringer Ingelheim Investigational Site

Pozuelo de Alarcón, , Spain

Site Status

1245.49.34016 Boehringer Ingelheim Investigational Site

Santiago de Compostela (La Coruña), , Spain

Site Status

1245.49.34041 Boehringer Ingelheim Investigational Site

Valencia, , Spain

Site Status

1245.49.75016 Boehringer Ingelheim Investigational Site

Kharkiv, , Ukraine

Site Status

1245.49.75007 Boehringer Ingelheim Investigational Site

Kiev, , Ukraine

Site Status

1245.49.75014 Boehringer Ingelheim Investigational Site

Kiev, , Ukraine

Site Status

1245.49.75015 Boehringer Ingelheim Investigational Site

Kiev, , Ukraine

Site Status

1245.49.75013 Boehringer Ingelheim Investigational Site

Kyiv, , Ukraine

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Belgium Bulgaria Colombia Czechia Finland France Germany Guatemala Mexico Peru Russia Spain Ukraine

References

Explore related publications, articles, or registry entries linked to this study.

Tuttle KR, Levin A, Nangaku M, Kadowaki T, Agarwal R, Hauske SJ, Elsasser A, Ritter I, Steubl D, Wanner C, Wheeler DC. Safety of Empagliflozin in Patients With Type 2 Diabetes and Chronic Kidney Disease: Pooled Analysis of Placebo-Controlled Clinical Trials. Diabetes Care. 2022 Jun 2;45(6):1445-1452. doi: 10.2337/dc21-2034.

Reference Type DERIVED
PMID: 35472672 (View on PubMed)

Rosenstock J, Jelaska A, Frappin G, Salsali A, Kim G, Woerle HJ, Broedl UC; EMPA-REG MDI Trial Investigators. Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes. Diabetes Care. 2014 Jul;37(7):1815-23. doi: 10.2337/dc13-3055. Epub 2014 Jun 14.

Reference Type DERIVED
PMID: 24929430 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2010-019968-37

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

1245.49

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 135585 XX in Patients With Type 2 Diabetes
NCT01282970 COMPLETED PHASE1
A Phase 1 Single/Multiple Dose Study Of PF-06293620 To Assess Safety, Tolerability And Pharmacokinetics In Subjects With Type 2 Diabetes Mellitus
NCT02211261 COMPLETED PHASE1
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 1356 BS in Patients With Type 2 Diabetes
NCT02183350 COMPLETED PHASE1
Efficacy and Safety of BI 1356 (Linagliptin) Versus Placebo in Type 2 Diabetic Patients With Insufficient Glycemic Control
NCT00621140 COMPLETED PHASE3
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Doses of BI 187004 in Patients With Type 2 Diabetes Mellitus
NCT01874483 COMPLETED PHASE1
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 44847 in Female and Male Patients With Type 2 Diabetes
NCT02211963 COMPLETED PHASE1
Empagliflozin (BI 10773) Comprehensive add-on Study in Japanese Subjects With Type 2 Diabetes Mellitus
NCT01368081 COMPLETED PHASE3
A Study to Test the Combination of Two Different Kinds of Medications for the Treatment of Diabetes
NCT00853151 COMPLETED PHASE1
A Study of LY3025876 in Participants With Diabetes
NCT01870297 COMPLETED PHASE1
A Phase IIA Study of BMS-512148 to Assess Safety, Exposure, and Biological Effects in Stable Type 2 Diabetic Subjects
NCT00162305 COMPLETED PHASE2
BI 1356 BS in Japanese Patients With Type 2 Diabetes Mellitus
NCT02183324 COMPLETED PHASE2
Safety and Tolerability of Ascending Intravenous Doses of PF-05231023 In Adult Subjects With Type 2 Diabetes
NCT01396187 COMPLETED PHASE1
Pharmacokinetics and Pharmacodynamics Trial With Linagliptin (BI 1356) 5mg in African American Type 2 Diabetic Patients
NCT00935220 COMPLETED PHASE1
Multiple Ascending Dose Study of BMS-820132 in Patients With Type 2 Diabetes
NCT01290575 COMPLETED PHASE1
Study to Evaluate the Safety and Tolerability of PBI-4050 in Type 2 Diabetes Patients With Metabolic Syndrome
NCT02562573 COMPLETED PHASE2
Assessment of the Safety, Tolerability and Pharmacodynamics After Administration of One Dose of AZD8601 to Male Patients With Type II Diabetes Mellitus (T2DM)
NCT02935712 COMPLETED PHASE1
30 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by a Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes for up to 54 Weeks
NCT01183013 COMPLETED PHASE3
A Trial of BMS-512148 in Patients With Type 2 Diabetes Mellitus
NCT00263276 COMPLETED PHASE2
Safety Study of BMS-903452 in Healthy Subjects (Panel 1-7) & Relative Bioavailability of the Crystalline and Amorphous Forms of BMS-903452 [Panels 4, 6, 11 & 12(Part A)], and Subjects With Type 2 Diabetes Mellitus (Part B)
NCT01240980 COMPLETED PHASE1
Safety Study to Evaluate BMS-767778 in Healthy Subjects and Subjects With Type 2 Diabetes Mellitus (T2DM)
NCT00707590 TERMINATED PHASE1
Study of the Safety and Efficacy of MK-8521 Compared to Placebo and a Diabetes Drug in Participants With Type 2 Diabetes Mellitus (MK-8521-003)
NCT01982630 COMPLETED PHASE1
Study of RO6807952 in Patients With Diabetes Mellitus Type 2
NCT01516476 TERMINATED PHASE2
Safety and Pharmacokinetics Study of XOMA 052 in Subjects With Type 2 Diabetes Mellitus
NCT00513214 COMPLETED PHASE1/PHASE2
A 6-Week Study To Determine The Safety And Effect Of An Investigational Drug On Adults With Type 2 Diabetes Mellitus Taking Metformin
NCT02053103 TERMINATED PHASE2
Efficacy and Safety of Linagliptin (BI 1356) in Black/African Americans With Type 2 Diabetes With a MTT Sub-study
NCT01194830 COMPLETED PHASE3